FDA Extends Review Timeline For Aldeyra's Reproxalap NDA In Dry Eye Disease

Aldeyra Therapeutics said the FDA extended the PDUFA target action date for reproxalap in dry-eye disease to March 16, 2026 (NDA filed June 16, 2025; accepted July 16, 2025) after the agency requested and the company submitted a Clinical Study Report from a field trial that showed activity versus vehicle but failed to meet the primary symptom endpoint; the CSR was deemed a major amendment that triggered the review extension. The FDA had previously received safety data, raised no other issues at a December meeting, and provided a draft label that Aldeyra has responded to, with the agency indicating it would communicate proposed labeling changes and any potential postmarketing requirements by Feb. 16, 2026 if no major deficiencies are identified. The announcement heightened approval timing uncertainty and the stock fell sharply, down about 12% in regular trading and a further ~17% after hours.

Analysis

Aldeyra Therapeutics reported that the FDA has extended the PDUFA target action date for reproxalap to March 16, 2026; the NDA was filed June 16, 2025 and accepted July 16, 2025 as a complete class 2 response with an initial action date of December 16, 2025. The extension followed a December 12, 2025 FDA request for the Clinical Study Report (CSR) from a field trial that, while showing activity versus vehicle, failed to meet the primary symptom-improvement endpoint; the CSR was submitted the same day and deemed a major amendment. The agency had previously received safety data in August 2025 and reported no additional issues at the December meeting; Aldeyra also exchanged a draft product label with FDA and has responded to it. The company’s shares reacted sharply, closing at $3.99 down 12.11% and falling to $3.32 (down 16.79%) in after-hours trading, reflecting increased regulatory uncertainty and a more binary near-term approval outlook pending proposed labeling and any postmarketing requirements expected by Feb. 16, 2026 if no further deficiencies are identified.

Key Decisions for Investors

• Avoid initiating new long positions until FDA communications on proposed labeling and any postmarketing requirements around Feb. 16, 2026 clarify the agency’s stance
• Consider reducing exposure or employing short-term hedges given the NDA amendment and the trial’s failure to meet the primary symptom endpoint which increases downside binary risk
• If holding shares for a potential longer-term recovery, wait for the March 16, 2026 PDUFA outcome and detailed labeling/PMR language before adding to positions
• Monitor company disclosures for the CSR details, FDA feedback, and any follow-up safety or efficacy analyses as these will materially influence approval probability and commercial labeling